ESMO 2018 | Considerations for the long-term effects of androgen deprivation therapy

Bertrand Tombal, MD, PhD, of Cliniques Saint-Luc University, Brussels, Belgium, assesses the long term risks associated with androgen deprivation therapy for prostate cancer patients. Prof. Tombal speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, stressing the importance of patient monitoring and the promotion of lifestyle changes in patients to limit the effects of toxicity from the drug.